The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis ...
Povorcitinib (INCB-54707) is under development for the treatment of prurigo nodularis, hidradenitis suppurativa, asthma, chronic spontaneous urticaria and nonsegmental vitiligo. The drug candidate is ...
Hidradenitis suppurativa is more common among patients with Crohn disease (CD) than ulcerative colitis (UC), yet bowel obstruction affects both CD and UC.